Treatment and prognostic impact of transient leukemia in neonates with Down syndrome

Blood

Volumn 111, Issue 6, 2008, Pages 2991-2998

  Klusmann, Jan Henning ^a   Creutzig, Ursula ^b   Zimmermann, Martin ^a   Dworzak, Michael ^c   Jorch, Norbert ^d   Langebrake, Claudia ^e   Pekrun, Arnulf ^f   Macakova Reinhardt, Katarina ^a   Reinhardt, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d Krankenanstalten Gilead GmbH   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f KLINIKUM BREMEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ARTICLE; ASCITES; BLEEDING; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE COURSE; DOWN SYNDROME; EVENT FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELOID LEUKEMIA; NEWBORN; OVERALL SURVIVAL; PLEURA EFFUSION; PREMATURE LABOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT INDICATION; GENETICS; IMMUNOPHENOTYPING; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

DOWN SYNDROME; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT, NEWBORN; LEUKEMIA; MALE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 42449104896     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-118810     Document Type: Article

References (38)

1. Creutzig U, Ritter J. Vormoor J, et al. Transient myeloproliferative disorders and acute leukaemias in infants with Down's syndrome. Contrib Oncol. 1990;41:75-84.
2. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM. Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128-2131.
3. Langebrake C, Creutzig U. Reinhardt D. Immunophenotype of down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217:126-134.
4. Massey GV Zipursky A. Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107:4606-4613.
5. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993; 15:392-399.
6. Dixon N, Kishnani PS, Zimmerman S. Glinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. Am J Med Genet C Semin Med Genet. 2006;142:149-157.
7. Isaacs H Jr. Fetal and neonatal leukemia. J Pediatr Hematol Oncol. 2003;25:348-361.
8. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2:429-436.
9. Creutzig U, Reinhardt D, Diekamp S, Dworzak M. Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19:1355-1360.
10. Ravindranath YAbella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80:2210-2214.
11. Ge Y, Dombkowski AA, LaFiura KM, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocyte leukemia. Blood. 2006;107:1570-1581.
12. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99:245-251.
13. Wechsler J, Greene M, McDevitt MA; et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
14. Mundschau G, Gurbuxani S, Gamis AS, Greene ME. Arceci RJ. Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300.
15. Hollanda LM, Lima CS, CunhaAF et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006;38:807-812.
16. Li Z, Godinho FJ; Klusmann JH, Garriga-Canut M. Yu C. Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37: 613-619.
17. Bourquin JP, Subramanian A. Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006;103:3339-3344.
18. Langebrake C, Klusmann JH Wortmann K, Kolar M, Puhlmann U, Reinhardt D. Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. Haematologica. 2006;91:1473-1480.
19. Klusmann JH. Reinhardt D. Hasle H. et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia. 2007;21: 1584-1587.
20. Gattenloehner S. Chuvpilo S, Langebrake C. et al. Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood. 2007;110:2027-2033.
21. Zipursky A. Transient leukaemia: a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003;120:930-938.
22. Al Kasim F, Doyle JJ, Massey GV, Weinstein HJ, Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9-13.
23. Dormann S, Kruger M, Hentschel R, et al. Lifethreatening complications of transient abnormal myelopoiesis in neonates with Down syndrome. Eur J Pediatr. 2004;163:374-377.
24. Creutzig U, Ritter J. Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19: 2705-2713.
25. Heiner CR; Hunkapiller KL, Chen SM; Glass Jl, Chen EY Sequencing multimegabase-template DNA with BigDye terminator chemistry. Genome Res. 1998;8:557-561.
26. Chenna R, Sugawara H, Koike T et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003;31:3497-3500.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958:53:457-481.
28. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
29. Kalbfleisch JD. Prentice RL. The statistical analysis of failure time data. 1st ed. New York: John Wiley; 1980.
30. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
31. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187.
32. Reinhardt D, Diekamp S, Langebrake C, et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia. 2005;19:1495-1496.
33. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia. Am J Dis Child. 1957; 94:289-293.
34. ZipurskyA, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21:97-101.
35. Rosch G, Steinbicker V Kropf S. Down's syndrome: the effects of prenatal diagnosis and demographic factors in a region of the eastern part of Germany. Eur J Epidemiol. 2000;16:627-632.
36. Matsuoka S. Tsuji K, Hisakawa H, et al. Generation of definitive hematopoietic stem cells from murine early yolk sac and paraaortic splanchnopleures by aorta-gonad-mesonephros regionderived stromal cells. Blood. 2001;98:6-12.
37. Oren I, Goldman A, Haddad N, Azzam Z, Krivoy N, Alroy G. Ascites and pleural effusion secondary to extramedullary hematopoiesis. Am J Med Sci. 1999;318:286-288.
38. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome: a report of 40 children of the AML-BFM Study Group. Leukemia. 1996;10:1677-1686.